CagriSema vs Zepbound: Why Zepbound Leads on Weight Loss
Medically reviewed by Medical Advisory Board Last reviewed 2026-09-14
Novo Nordisk's head-to-head REDEFINE 4 trial showed tirzepatide ahead of CagriSema on weight reduction while CagriSema awaits FDA review.
Zepbound is FDA-approved and available in pharmacies today. CagriSema remains an experimental combination drug that Novo Nordisk submitted to the FDA in December 2025, so patients cannot access it outside clinical trials. In Novo Nordisk's direct REDEFINE 4 trial, tirzepatide numerically outperformed CagriSema on weight reduction, and CagriSema failed to demonstrate statistical non-inferiority. Patients who need treatment today have no clinical reason to wait for CagriSema.
Zepbound holds the clear advantage over CagriSema because it is FDA-approved today and outperformed it in direct trial comparisons. At The Metabolic Journal, we analyze clinical trial releases and metabolic research to help readers make sense of complex prescription decisions. Both medications target chronic weight management through weekly subcutaneous injections.
Eli Lilly manufactures Zepbound and distributes it commercially across retail pharmacies. CagriSema is not available to patients. Novo Nordisk submitted the experimental drug to the Food and Drug Administration (FDA) in December 2025, but regulatory review is still ongoing.
Partner · Opt Health
Want medical weight loss instead of another diet?
Opt Health prescribes and monitors GLP-1 therapy against real labs — insulin, A1C, lipids, thyroid, hormones — so the plan fits your physiology rather than a generic protocol. Medication ships to your door.
See Opt Health's weight-loss program →This availability gap shapes how patients must view this comparison. Our reviews of Wegovy vs Zepbound and Zepbound vs Ozempic evaluate therapies you can fill right now. In contrast, evaluating CagriSema mirrors our analysis of retatrutide vs tirzepatide by comparing an unapproved pipeline molecule against an approved standard.
CagriSema vs Zepbound at a Glance
Zepbound and CagriSema represent two distinct pharmacological approaches for adults managing obesity. The primary differences involve regulatory approval and head-to-head efficacy data. Zepbound is fully approved and sold in pharmacies today.
| Factor | CagriSema | Zepbound |
|---|---|---|
| Active ingredient and drug class | Cagrilintide 2.4 mg (amylin receptor agonist) + semaglutide 2.4 mg (GLP-1 receptor agonist) | Tirzepatide (dual GLP-1 and GIP receptor agonist) |
| FDA approval status | Investigational, unapproved (NDA submitted December 2025) | FDA-approved for chronic weight management and obstructive sleep apnea |
| Administration schedule and route | Subcutaneous injection once weekly | Subcutaneous injection once weekly across six strengths (2.5 mg to 15 mg) |
| Primary monotherapy trial weight loss | 22.7% mean loss at 68 weeks (REDEFINE 1, efficacy estimand) | Roughly 20.9% average loss at 72 weeks (SURMOUNT-1, 15 mg dose) |
| Head-to-head trial result (REDEFINE 4) | 23.0% loss at 84 weeks under efficacy estimand (did not meet non-inferiority) | 25.5% loss at 84 weeks under efficacy estimand (tirzepatide 15 mg) |
| Approved delivery formats | Not commercially available | Single-dose prefilled pen, single-dose vial, and multi-dose vial |
| Primary pharmaceutical manufacturer | Novo Nordisk | Eli Lilly |
CagriSema remains an investigational candidate awaiting an initial regulatory decision from the FDA. The table below outlines how these two therapies compare across mechanism, dosing, clinical trials, and commercial status.
| Dimension | CagriSema | Zepbound |
|---|---|---|
| Active ingredient | Cagrilintide 2.4 mg + semaglutide 2.4 mg | Tirzepatide |
| Mechanism of action | Amylin receptor agonist + GLP-1 receptor agonist | Dual GLP-1 and GIP receptor agonist |
| Regulatory status | Investigational (submitted December 2025) | FDA-approved |
| Dosing frequency | Once weekly subcutaneous injection | Once weekly subcutaneous injection |
| Headline trial weight loss | 22.7% at 68 weeks (REDEFINE 1) | Roughly 20.9% at 72 weeks (SURMOUNT-1) |
| REDEFINE 4 head-to-head result | 23.0% weight reduction at 84 weeks | 25.5% weight reduction at 84 weeks (15 mg dose) |
| Primary manufacturer | Novo Nordisk | Eli Lilly |
Zepbound maintains an advantage in patient access. CagriSema combines two distinct hormone receptor agonists into a single injection, whereas Zepbound delivers a single dual-agonist molecule. The differences in trial design and reported weight reduction help explain why clinicians view them differently.
What Each Drug Actually Is
Zepbound contains tirzepatide, an active compound that activates both GLP-1 and GIP receptors. Eli Lilly developed the drug for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Regulators also approved Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Patients inject Zepbound subcutaneously once every seven days across six dose strengths ranging from 2.5 mg to 15 mg. Eli Lilly offers three physical formats. The manufacturer ships single-dose prefilled pens, single-dose vials, and multi-dose vials to provide flexibility during weekly administration, as covered in our guide on Zepbound vials vs pen.
CagriSema is an investigational fixed-dose combination therapy developed by Novo Nordisk. The formulation contains cagrilintide 2.4 mg, which is a long-acting amylin receptor agonist, and semaglutide 2.4 mg, a GLP-1 receptor agonist. Novo Nordisk submitted CagriSema to the FDA in December 2025 for a weight-management indication based on the REDEFINE 1 and REDEFINE 2 trials.
FDA Approval Status and Current Availability
CagriSema is not FDA-approved and is not commercially available in the United States. Pharmacies cannot stock it. Novo Nordisk submitted its regulatory application to the FDA in December 2025 based on the REDEFINE 1 and REDEFINE 2 trials.
The FDA has not issued an official approval decision date for CagriSema. Patients should not plan medical care around speculative approval timelines. Regulatory evaluations can take considerable time or require additional clinical data before reaching a final marketing verdict.
Zepbound holds active regulatory clearance and widespread commercial availability. Physicians prescribe Zepbound every day for adult weight management and sleep apnea. Patients who qualify under the FDA indication can obtain the medication through standard pharmacy channels immediately.
CagriSema vs Zepbound Weight Loss Results
Clinical trial data shows that Zepbound's active ingredient delivered greater average weight loss than CagriSema in direct comparative research. That outcome surprised many observers. Earlier standalone trials suggested both therapies produced average body weight reductions exceeding twenty percent.
Novo Nordisk evaluated CagriSema in the REDEFINE 1 trial, published in the New England Journal of Medicine on June 22, 2025. The 68-week trial enrolled 3,417 adults without diabetes. Under the trial's efficacy estimand, CagriSema 2.4 mg/2.4 mg achieved a mean 22.7% weight reduction compared to 2.3% for placebo. Furthermore, 97.6% of CagriSema participants lost at least 5% of their starting body weight under that same estimand.
In Zepbound's SURMOUNT-1 clinical trial, the highest studied dose of tirzepatide produced roughly 20.9% average weight loss at 72 weeks. That trial established tirzepatide as an exceptionally effective single-agent injectable for weight reduction.
The clearest comparison between these compounds came from the REDEFINE 4 head-to-head trial, announced by Novo Nordisk on February 23, 2026. This open-label, 84-week trial tested CagriSema directly against tirzepatide 15 mg in 809 people with obesity and at least one comorbidity. Baseline body weight averaged 114.2 kg.
CagriSema did not meet its primary endpoint of statistical non-inferiority to tirzepatide on weight loss. Under the full-adherence efficacy estimand, CagriSema produced 23.0% weight loss versus 25.5% for tirzepatide 15 mg at 84 weeks. The arithmetic favored tirzepatide.
Under the treatment-regimen estimand reflecting real-world adherence, CagriSema produced 20.2% weight reduction while tirzepatide delivered 23.6%. Novo Nordisk's own head-to-head trial found tirzepatide numerically ahead across both primary measures.
Reported Side Effects and Tolerability Profiles
Both CagriSema and Zepbound show tolerability profiles characterized primarily by gastrointestinal symptoms. These symptoms reflect known peptide effects. Across its clinical trials, Novo Nordisk reported CagriSema's safety profile as safe and well-tolerated among study participants.
Gastrointestinal adverse events were the most common side effects reported for CagriSema, presenting mostly as mild-to-moderate events that diminished over time. These events match the adverse reactions typically seen with GLP-1 receptor agonists, including Zepbound. Nausea and related digestive complaints often fade as patients adapt to therapy.
Treatment Costs and Commercial Availability
CagriSema has no approved price in the United States because it remains unapproved by the FDA. No retail pricing exists. Any speculation regarding manufacturer copay programs or insurance coverage tiers for CagriSema cannot be verified until commercial approval occurs.
Zepbound carries established commercial pricing, but out-of-pocket costs vary based on insurance benefits and pharmacy copay cards. Manufacturer cash-pay pricing changes over time. We recommend that patients check current pricing directly on Zepbound's own site to confirm terms for self-pay options and commercial savings cards.
This financial reality dictates who each medication serves today. A patient requiring treatment now has no reason to wait on CagriSema, given its unapproved status and trial results. Zepbound offers immediate access and proven efficacy.
What to Look For in a Body-Composition Scale
A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.
Frequently Asked Questions
Is CagriSema better than Zepbound?
No, clinical trial results do not show that CagriSema is better than Zepbound. In the REDEFINE 4 head-to-head trial announced on February 23, 2026, tirzepatide 15 mg produced greater weight loss than CagriSema 2.4 mg/2.4 mg. CagriSema did not meet its primary endpoint of statistical non-inferiority to tirzepatide. Under the efficacy estimand at 84 weeks, tirzepatide achieved 25.5% weight reduction versus 23.0% for CagriSema. Zepbound also holds full FDA approval, while CagriSema remains unapproved.
When will CagriSema be available?
CagriSema is not available yet, and no official commercial release date exists. Novo Nordisk submitted the medication to the FDA for regulatory review in December 2025. The FDA has not issued an approval decision. Until regulatory agencies finish their review and grant marketing clearance, CagriSema cannot be purchased or prescribed in the United States.
Can CagriSema help with weight loss?
Yes, clinical trials confirm that CagriSema produces substantial weight reduction. In the REDEFINE 1 trial published in the New England Journal of Medicine, CagriSema produced a mean 22.7% weight loss at 68 weeks under the efficacy estimand. That compared to 2.3% for placebo. However, in the REDEFINE 4 trial against tirzepatide, CagriSema's 23.0% efficacy-estimand weight loss fell short of tirzepatide's 25.5% result.
What is better than Zepbound?
Within published clinical trial evidence, no weight-loss medication has demonstrated superiority over Zepbound's active ingredient in direct comparative testing. In the REDEFINE 4 trial, Novo Nordisk's CagriSema failed to prove non-inferiority against tirzepatide 15 mg. Tirzepatide produced 25.5% weight loss versus 23.0% for CagriSema under the full-adherence estimand at 84 weeks. Tirzepatide remains the leading option in head-to-head weight management trials.
Topic updates
Get the weekly metabolic health roundup
Insulin resistance, blood sugar, visceral fat, GLP-1 plateaus, metabolic syndrome, and weight-loss physiology.
Want weight loss handled by a physician who works from your labs? See how Opt Health does it →
Check Where You Stand
Take our free health assessment to understand your metabolic, hormonal, and recovery risk factors — and get personalized recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results
Related Comparisons
-
Foundayo vs Zepbound: New Oral GLP-1 Pill vs the Strongest Weekly Injection Compared
Foundayo vs Zepbound: new daily GLP-1 pill vs the strongest weekly dual-mechanism injection.
-
Saxenda vs Zepbound: Daily Liraglutide vs Weekly Dual-action Tirzepatide Compared
Saxenda vs Zepbound: daily liraglutide vs weekly dual-action tirzepatide — trial results compared.
-
Wegovy vs Zepbound: Same Mechanism, Different Numbers — Which FDA-approved Weight-loss Injection Wins?
Wegovy vs Zepbound: FDA-approved weight-loss injections compared on results, CV data, and cost.
See more related comparisons
-
Zepbound vs Ozempic: On-label Weight-loss Approval vs Off-label Diabetes Drug Compared
Zepbound vs Ozempic: on-label weight-loss approval vs off-label diabetes drug compared.
-
Mounjaro vs Zepbound: Same Drug (Tirzepatide), Different Approval — Insurance and Access Explained
Mounjaro vs Zepbound: same drug (tirzepatide), different brand — insurance and access explained.
-
Zepbound Alternatives: 6 Options Compared for Weight Management
Zepbound alternatives ranked: Wegovy, Mounjaro, off-label Ozempic, compounded GLP-1, metformin.
-
Contrave vs Zepbound: Which Fits Your Weight-loss Goal, on Trial Results, Safety, and Cost
Contrave vs Zepbound: trial weight-loss data, the POMC/naltrexone mechanism, contraindications, and annual cost math compared.
-
Zepbound vs Metformin: Dual-agonist Weight Loss vs Cheap First-line Glucose Control, Compared
Zepbound vs metformin: mechanism, SURMOUNT-1 weight-loss data, cost, and when each (or a combination) fits.
Affiliate disclosure: The Metabolic Journal is reader-supported. Some links above are affiliate or referral links and we may earn a commission at no extra cost to you. As an Amazon Associate we earn from qualifying purchases. Products are chosen on the merits; commissions never influence what we recommend. This is general information, not medical advice — talk to your clinician before acting.